Matthew Selmon, MD
Interventional Cardiology · Austin, TXNPI 1316990922
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 243 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,324 and has fallen 57.6% since, to $561 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 243 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Abiomed$493
- Johnson & Johnson$413
- Actelion Pharmaceuticals US, Inc.$410
- Boston Scientific$333
- Abbott$325
- plus $2K from 25 others
Across 26 payments — averaging $849.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$14K
- Tryton Medical, Inc.$8K
What the payments were for
- Food & beverage$5,278100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 80 | $1,197 |
| Abiomed | 21 | $493 |
| Johnson & Johnson | 25 | $413 |
| Actelion Pharmaceuticals US, Inc. | 23 | $410 |
| Boston Scientific | 11 | $333 |
| Abbott | 10 | $325 |
| Medtronic(2 entities) | 8 | $226 |
| Acist Medical Systems, Inc. | 5 | $191 |
| Novartis | 9 | $178 |
| Angiodynamics, Inc. | 2 | $165 |
| Penumbra, Inc. | 2 | $160 |
| Biotronik Inc. | 3 | $153 |
| BD | 2 | $121 |
| Inari Medical, Inc. | 1 | $116 |
| Tactile Systems Technology Inc | 5 | $88 |
| Impulse Dynamics (USA) Inc. | 4 | $87 |
| Shockwave Medical, Inc | 4 | $86 |
| Sanofi-aventis U.S. LLC | 5 | $79 |
| Avinger Inc. | 1 | $62 |
| Terumo Medical Corporation | 1 | $48 |
| Endovascular Engineering Inc. | 4 | $48 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $39 |
| Philips North America LLC | 1 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $38 |
| Novo Nordisk | 1 | $33 |
| Chiesi USA, Inc. | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Biocompatibles, Inc. | 1 | $20 |
| Atricure, Inc. | 1 | $20 |
| Cashflow Solutions, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Penumbra System$134
- FLOWTRIEVER CATHETER, S$116
- CT THROMBECTOMY SYSTEM KIT$116
- Ultreon$114
- Impella$106
How this compares
$5,278 in reported general payments places this provider in the 30th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 102 | $129,250 |
| Praluent PenAlirocumab | 29 | $27,237 |
| BrilintaTicagrelor | 16 | $15,423 |
| EliquisApixaban | 15 | $14,007 |
| Repatha PushtronexEvolocumab | 17 | $13,599 |
| Rosuvastatin Calcium | 158 | $2,492 |
| Prasugrel Hcl | 26 | $1,531 |
| Atorvastatin Calcium | 146 | $1,127 |
| Metoprolol Succinate | 62 | $1,113 |
| ClopidogrelClopidogrel Bisulfate | 72 | $992 |
| Valsartan | 38 | $919 |
| Metoprolol Tartrate | 87 | $799 |
| Losartan Potassium | 61 | $718 |
| Amlodipine Besylate | 81 | $659 |
| Lisinopril | 77 | $501 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Austin
- Francis ZidarAustin$433K
- Juhana KarhaAustin$147K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.